Activity of trimethoprim (TMP), sulphamethoxazole (SMX) and the combination against bacteroides fragilis group isolates

Gary L. Jackson-york, Brooks B. Gump, Dieter W. Gump

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The in-vitro efficacy of trimethoprim/sulphamethoxazole (TMP/SMX) was tested against 59 isolates belonging to the Bacteroides fragilis group of bacteria and was shown to be dependent upon the inoculum size. With an inoculum of 3 × 105 colony forming units (cfu), 98% of these isolates were susceptible to the combination, whereas with a higher inoculum of 106 cfu, 88% were susceptible. None of the isolates were susceptible to less than 2 mg/l of TMP, whereas 57 (97%) were susceptible to SMX at the lower inoculum and 21 (36%) at the higher inoculum. These data indicate that TMP/SMX has moderate activity against organisms of the Bact. fragilis group when tested at an inoculum of 106 cfu.

Original languageEnglish (US)
Pages (from-to)515-518
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume12
Issue number5
DOIs
StatePublished - Nov 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Activity of trimethoprim (TMP), sulphamethoxazole (SMX) and the combination against bacteroides fragilis group isolates'. Together they form a unique fingerprint.

  • Cite this